{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:58:02Z","timestamp":1781765882405,"version":"3.54.5"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.biopha.2022.112756","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:23:04Z","timestamp":1645748584000},"page":"112756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["There is nothing exempt from the peril of mutation \u2013 The Omicron spike"],"prefix":"10.1016","volume":"148","author":[{"given":"Tapan","family":"Behl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishnoor","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Khalid","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz A.","family":"Makeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Albratty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan A.","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112756_bib1","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1073\/pnas.1705628114","article-title":"Crystal structure of CO-bound cytochrome c oxidase determined by serial femtosecond X-ray crystallography at room temperature","volume":"114","author":"Ishigami","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biopha.2022.112756_bib2","unstructured":"Johns Hopkins Coronavirus Resource Center, (n.d). \u3008https:\/\/coronavirus.jhu.edu\/vaccines\/vaccines-faq\u3009 (accessed December 13, 2021)."},{"key":"10.1016\/j.biopha.2022.112756_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat. Hum. Behav."},{"key":"10.1016\/j.biopha.2022.112756_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2022.112756_bib5","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in boosting COVID-19 vaccine immune responses","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112756_bib6","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jiph.2021.08.011","article-title":"The future of COVID-19: a vaccine review","volume":"14","author":"Vashi","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.biopha.2022.112756_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.abh1766","article-title":"Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants","volume":"373","author":"Wang","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112756_bib8","doi-asserted-by":"crossref","unstructured":"Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern, (n.d.). \u3008https:\/\/www.who.int\/news\/item\/26\u201311-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern\u3009 (accessed December 9, 2021).","DOI":"10.47799\/pimr.0903.01"},{"key":"10.1016\/j.biopha.2022.112756_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102779","article-title":"Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies","volume":"126","author":"Kannan","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.biopha.2022.112756_bib10","unstructured":"Science Brief: Omicron (B.1.1.529) Variant | CDC, (n.d.). \u3008https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/scientific-brief-omicron-variant.html\u3009 (accessed December 9, 2021)."},{"key":"10.1016\/j.biopha.2022.112756_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbrc.2021.12.079","article-title":"Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor","volume":"590","author":"Lupala","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2022.112756_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization \u2013 implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.112756_bib13","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1126\/science.acx9738","article-title":"Where did 'weird' Omicron come from?","volume":"374","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112756_bib14","unstructured":"Haseltine W. Omicron: The Sum Of All Fears 2021. \u3008https:\/\/www.forbes.com\/sites\/williamhaseltine\/2021\/12\/08\/omicron-the-sum-of-allfears\/?sh=2ef4182d5b51\u3009."},{"key":"10.1016\/j.biopha.2022.112756_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2022.112756_bib16","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.cell.2021.02.042","article-title":"SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.112756_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.biopha.2022.112756_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109292","article-title":"Recurrent emergence of SARS-CoV-2 spike deletion H69\/V70 and its role in the Alpha variant B.1.1.7","volume":"35","author":"Meng","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2022.112756_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112756_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110428","article-title":"Cryo-EM structure of the SARS-CoV-2 omicron spike","author":"Cerutti","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2022.112756_bib21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells","volume":"78","author":"Hoffmann","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2022.112756_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1073\/pnas.2109905118","article-title":"Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biopha.2022.112756_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.112756_bib24","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesSARS-CoV-2 neutralizing antibody activity","volume":"217","author":"Schmidt","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109825","article-title":"B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination","volume":"37","author":"Arora","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2022.112756_bib26","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41422-021-00554-1","article-title":"Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants","volume":"31","author":"Xu","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2022.112756_bib27","unstructured":"Cao Y., Wang J., Jian F., et al. B.1.1.529 Escapes the Majority of SARS-CoV-2 Neutralizing Antibodies of Diverse Epitopes. BioRxiv 2021. \u300810.1101\/2021.12.07.4703922021.12.07.470392\u3009."},{"key":"10.1016\/j.biopha.2022.112756_bib28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.112756_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112756_bib30","doi-asserted-by":"crossref","first-page":"22311","DOI":"10.1073\/pnas.2010146117","article-title":"Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates","volume":"117","author":"Damas","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biopha.2022.112756_bib31","article-title":"Computational insights into differential interaction of mammalian angiotensin-converting enzyme 2 with the SARS-CoV-2 spike receptor binding domain","volume":"141","author":"Lupala","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib32","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgg.2021.12.003","article-title":"Evidence for a mouse origin of the SARS-CoV-2 Omicron variant","author":"Wei","year":"2021","journal-title":"J. Genet. Genom."},{"key":"10.1016\/j.biopha.2022.112756_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2021.102246","article-title":"The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues","volume":"45","author":"Khan","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.112756_bib36","unstructured":"C. Kuhlmann, C.K. Mayer, M. Claassen\u00a0et al., Breakthr. Infect. SARS-CoV-2 omicron Var. Boost. dose mRNA Vaccin. December 9, 2021 doi:\u00a010.2139\/ssrn.3981711.(SSRN)\u3008https:\/\/ssrn.com\/abstract=3981711\u3009."},{"key":"10.1016\/j.biopha.2022.112756_bib37","unstructured":"Pfizer. Pfizer and BioNTech Provide Update on Omicron Variant. Press release. Wednesday, December 08, 2021 - 06:54am. \u3008https:\/\/www.pfizer.com\/news\/press-release\/press-releasedetail\/pfizer-and-biontech-provide-update-omicron-variant\u3009. (Last accessed December 12, 2021."},{"key":"10.1016\/j.biopha.2022.112756_bib38","unstructured":"Billy J., Gardner A., Kilpatrick M. Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers. medRxiv 2021;12:21267594, \u300810.1101\/2021.12.10.21267594\u3009."},{"key":"10.1016\/j.biopha.2022.112756_bib39","unstructured":"Fortune. Health COVID-19 Vaccines. Singapore finds two breakthrough Omicron cases in residents who got COVID booster shots. (Last accessed December 12, 2021. \u3008https:\/\/fortune.com\/2021\/12\/09\/singapore-omicron-variant-covid-cases-breakthrough-vaccine-pfizer-biontech\/?queryly=related_article\u3009."},{"key":"10.1016\/j.biopha.2022.112756_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112756_bib41","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib42","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(21)01891-2","article-title":"SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1- S\/BNT162b2 vaccination","volume":"398","author":"Behrens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112756_bib43","article-title":"Protection against Covid-19 by BNT162b2 Booster across Age Groups","author":"Bar-On","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/d41586-021-02158-6","article-title":"COVID vaccine boosters: the most important questions","volume":"596","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112756_bib45","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in boosting COVID-19 vaccine immune responses","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112756_bib46","doi-asserted-by":"crossref","unstructured":"N. Andrews, J. Stowe, F. Kirsebom\u00a0et al., Eff. BNT162b2 (Comirnaty, Pfizer-BioNTech) covid-19 Boost. Vaccin. covid-19 Relat. symptoms Engl.: Test. Negat. case-Control Study medRxiv 11 2021 1266341 doi:\u00a010.1101\/2021.11.15.21266341.","DOI":"10.1101\/2021.11.15.21266341"},{"key":"10.1016\/j.biopha.2022.112756_bib47","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib48","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112756_bib49","article-title":"Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine","author":"Patalon","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib50","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.15585\/mmwr.mm7034e1","article-title":"New COVID-19 cases and hospitalizations among adults, by vaccination status - New York","volume":"70","author":"Rosenberg","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.biopha.2022.112756_bib51","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"C4591001 clinical trial group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib52","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112756_bib53","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112756_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2021.102242","article-title":"Omicron N501Y mutation among SARS-CoV-2 lineages: insilico analysis of potent binding to tyrosine kinase and hypothetical repurposed medicine","volume":"45","author":"Kazybay","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.112756_bib55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molcel.2020.08.006","article-title":"Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication","volume":"80","author":"Klann","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2022.112756_bib56","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hep.26404","article-title":"Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha","volume":"58","author":"Lupberger","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.112756_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005622","article-title":"EGFR interacts with the fusion protein of respiratory syncytial virus strain 2-20 and mediates infection and mucin expression","volume":"12","author":"Currier","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biopha.2022.112756_bib58","first-page":"177","article-title":"Genistein reduces the activation of AKT and EGFR, and the production of IL6 in cholangiocarcinoma cells involving estrogen and estrogen receptors","volume":"53","author":"Tanjak","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2022.112756_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1758-2946-6-13","article-title":"TCMSP: a database of systems pharmacology for drug discovery from herbal medicines","volume":"6","author":"Ru","year":"2014","journal-title":"J. Chemin."},{"key":"10.1016\/j.biopha.2022.112756_bib60","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1080\/10717544.2021.1977422","article-title":"Network pharmacology and experimental investigation of Rhizoma polygonati extract targeted kinase with herbzyme activity for potent","volume":"28","author":"Xie","year":"2021","journal-title":"Drug Deliv. Drug Deliv."},{"key":"10.1016\/j.biopha.2022.112756_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2020.104149","article-title":"Potential compound from herbal food of Rhizoma Polygonati for treatment of COVID-19 analyzed by network pharmacology: viral and cancer signaling mechanisms","volume":"77","author":"Mu","year":"2021","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.biopha.2022.112756_bib62","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1039\/D0NA00958J","article-title":"Herbal food processing generation of particle assembly mimicking enzymatic activity: the case of Rhizoma polygonati and other natural ingredients of traditional Chinese medicine","volume":"3","author":"Benassi","year":"2021","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.biopha.2022.112756_bib63","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.7150\/ijbs.63969","article-title":"Targeting the PI3K\/AKT pathway: a potential new weapon in the global fight against SARS-CoV-2?","volume":"17","author":"Santamaria","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2022.112756_bib64","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.7150\/ijbs.57810","article-title":"Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19","volume":"17","author":"Sun","year":"2021","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.biopha.2022.112756_bib65","article-title":"In the age of omicron variant: paxlovid raises new hopes of COVID-19 recovery","author":"Wang","year":"2021","journal-title":"Med. Virol."},{"key":"10.1016\/j.biopha.2022.112756_bib66","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2022.112756_bib67","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112756_bib68","first-page":"4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112756_bib69","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","author":"Zhao","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.biopha.2022.112756_bib70","doi-asserted-by":"crossref","unstructured":"Ullrich S., Ekanayake KB, Otting G., Nitsche C. Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332. bioRxiv. 2021. \u3008doi:10.1101\/2021.11.28.470226\u3009.","DOI":"10.1101\/2021.11.28.470226"},{"key":"10.1016\/j.biopha.2022.112756_bib71","article-title":"A tale of two antiviral targets\u2014and the COVID-19 drugs that bind them","author":"Cully","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112756_bib72","unstructured":"oral. Antivir. Treat. candidate Reduc. risk Hosp. or. death 89% interim Anal. phase 2\/3 EPIC-HR study 2021.Accessed November 5\u3008https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-novel-covid-19-oral-antiviral-treatment-candidate\u3009."},{"key":"10.1016\/j.biopha.2022.112756_bib73","article-title":"Protection against the omicron variant from previous SARS-CoV-2 infection","author":"Altarawneh","year":"2022","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2022.112756_bib74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/biology11020258","article-title":"Targeting the RBD of omicron variant (B.1.1.529) with medicinal phytocompounds to abrogate the binding of spike glycoprotein with the hACE2 using computational molecular search and simulation approach","volume":"11","author":"Hakami","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.biopha.2022.112756_bib75","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/ptr.5420","article-title":"Extract from ceratonia siliqua exhibits depigmentation properties","volume":"29","author":"Lall","year":"2015","journal-title":"Phytother. Res."},{"key":"10.1016\/j.biopha.2022.112756_bib76","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.phytochem.2007.08.003","article-title":"Flavones from Struthiola argentea with anthelmintic activity in vitro","volume":"69","author":"Ayers","year":"2008","journal-title":"Phytochemistry"},{"key":"10.1016\/j.biopha.2022.112756_bib77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jep.2004.09.057","article-title":"Antimicrobial activity, toxicity and the isolation of a bioactive compound from plants used to treat sexually transmitted diseases","volume":"96","author":"Tshikalange","year":"2005","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2022.112756_bib78","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/np800333r","article-title":"Bioactive diterpenes and other constituents of croton steenkampianus","volume":"71","author":"Adelekan","year":"2008","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.biopha.2022.112756_bib79","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.112756_bib80","article-title":"Enhanced fusogenicity and pathogenicity of SARS-CoV-2 delta P681R mutation","author":"Saito","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112756_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts tropism and fusogenicity","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112756_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.106198","article-title":"Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt","volume":"97","author":"Dhawan","year":"2022","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.biopha.2022.112756_bib83","article-title":"Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert","author":"Gao","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.biopha.2022.112756_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112756_bib85","article-title":"Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study","author":"Andrews","year":"2021","journal-title":"medRxiv"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222001445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222001445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:33:24Z","timestamp":1781764404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222001445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":85,"alternative-id":["S0753332222001445"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112756","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"There is nothing exempt from the peril of mutation \u2013 The Omicron spike","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112756"}}